Pablo G. Legorreta insider trades

Open-market stock purchases and sales by Pablo G. Legorreta, CEO, Chairman of the Board at Royalty Pharma plc, from SEC Form 4 filings since Nov 6, 2019.

Track record: 88% of 8 scored buys are up 5% or more since purchase, averaging +70%.

Recent trades

DateStockTradeValue
Aug 7, 2026RPRX Royalty Pharma plcSold (not open market)—
Aug 5, 2026RPRX Royalty Pharma plcBought (not open market)—
May 28, 2026PROK Prokidney CorpBought (not open market)—
May 6, 2026RPRX Royalty Pharma plcBought (not open market)—
Feb 11, 2026RPRX Royalty Pharma plcBought (not open market)—
Nov 5, 2025RPRX Royalty Pharma plcBought (not open market)—

Companies traded

  • RPRX Royalty Pharma plc: 7 buys, last Aug 7, 2026
  • PROK Prokidney Corp: 1 buy, last May 28, 2026
  • EPZM Epizyme, Inc: 1 buy, last Aug 12, 2022

Get free alerts when Pablo G. Legorreta files a new trade →